Trial Profile
A phase II study of Avelumab + stereotactic ablative body radiosurgery (SABR) for metastatic castration-resistant prostate cancer (mCRPC). To assess radiographic progression-free survival (rPFS).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2022
Price :
$35
*
At a glance
- Drugs Avelumab (Primary)
- Indications Adenocarcinoma; Bone metastases; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ICE-PAC
- 13 Feb 2021 Following enrolment of 14 pts, a protocol amendment allowed avelumab beyond 12 cycles in pts with disease control at 24 weeks, as per Results presented at the 2021 Genitourinary Cancers Symposium
- 13 Feb 2021 Results presented at the 2021 Genitourinary Cancers Symposium
- 08 Jun 2018 New trial record